Meet the Innovator’s Pitch Challenge (IPC) Finalists of RESI Partnering Week

2 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Life Science Nation (LSN) is pleased to announce the Innovator’s Pitch Challenge (IPC) finalists who will be presenting at the upcoming RESI Partnering Week, September 13-17. The IPC continues to see a record number of applicants, establishing itself as a differentiated and effective platform to showcase innovative technologies during a virtual conference age.

Each participating company will have a dedicated landing page with their pitch video and supplementary materials and will participate in a live Q&A session with investors and industry experts providing feedback and questions, which will help companies better prepare for future investor meetings, understand investor perspectives, and enhance their visibility and network. Many past participants have credited the IPC to unexpected follow-up meetings and new connections.

RESI Partnering Week attendees do not want to miss out on these engaging sessions! If you are not registered, it is not too late – you can register here. If you are an active investor interested in getting involved with these sessions, please reach out to research@lifesciencenation.com for more information.

Below are the participating companies – please click on their logos to learn more!

 
 
490

Focused Workshops at RESI Partnering Week

2 Sep

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI Partnering Week (RPW) – September 13-17, 2021 – is much more than an opportunity to meet one-on-one with investors and other key players in the life science space. The conferences also offer quality, live-streaming workshops on an array of hot topics that are particularly relevant to the space, sponsored by our many great partners. The live format allows for interactive Q&A and makes the sessions more dynamic.

Here are some examples of great content you can expect at RPW:

September 13, 5 PM EDT | Digital RESI September

Why US Biotechs are Coming to Australia and How They are Saving in Regulatory Timelines and Considerable Costs
Yvonne Lungershausen, CEO, Avance Clinical

Learn how U.S. biotechs expedite their early phase clinical research program. With no IND required to start your clinical program in Australia, biotechs are able to save up to a year in regulatory timelines and considerable costs.

September 14, 9 AM EDT | Digital RESI September

Company Valuation for Fundraising – Trends and Tools
Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland
Gergely Ivanyi, PharmD, Business Analyst, Venture Valuation

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, it’s important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don’ts when speaking with investors and look at how to value a life science company with no revenues.

September 14, 3PM EDT | Digital RESI September | RESI AI (Pre-Recorded) | RESI Longevity (Pre-Recorded)

Fundraising Bootcamp
Dennis Ford, CEO, Life Science Nation

The Fundraising Boot Camp provides a top-to-bottom master class on outbound global fundraising. Topics to be covered include the Changing Investor Landscape, New Categories of Life Science Investors, Debunking the Top 10 Old Myths in Fundraising, Planning & Infrastructure for an Outbound Fundraising Campaign, Building Your Brand Through Consistent Messaging and Key Components of Fundraising Marketing Collateral. It will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and how to reach out to a list of global investors.

September 15, 11 AM EDT | Digital RESI September

Negotiating Term Sheets: What’s Best for the Company and What’s Best for You?
Instructor to be Announced, McDermott Will & Emery

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

September 15, 1 PM EDT | Digital RESI September

Financing Scientific Instrumentation as a Startup Company
Darren Platt, President, Demetrix
Bryan Leavitt, Managing Partner, Fountainhead Investment Partner
Chad Kobold, Director of Business, Development, Bold View Capital

Over the last several years, a record number of exciting life sciences start-ups have come online. Most of these start-up companies need scientific instrumentation to support their research. But when funds are limited, how can these companies get the instrumentation needed to hit their growth milestones? Workshop will kick off with an overview of the leasing market for start-ups. Expert panel will share their own experiences going through the leasing process and offer valuable lessons learned. 

September 17, 11 AM EDT | RESI AI

How to Go to Market: Commercializing AI-Based Health Technologies
Richie Bavasso, MBA, Co-Founder & CEO, nQ Medical Inc.
Carolyn Metnick, JD, Partner, McDermott Will & Emery
Fahad Rahman, MBA, Co-Founder & CEO, Lumi Health
Michael Ryan, JD, Partner, McDermott Will & Emery
Dale Van Demark, JD, Partner, McDermott Will & Emery

This workshop, hosted by our Title Sponsor McDermott Will & Emery, will focus on the various options for and the legal considerations involved with commercializing AI-based healthcare technologies, including regulatory and data strategies. Learn about the range of options, from R&D use to consumer products, from leading members of McDermott’s digital health practice and companies that have blazed the trail.

Sign up to participate at RESI Partnering Week, September 13-17, and learn more about sponsoring workshops at future events!

490

There’s Still Time to Join the Global Roadshow Prep Course

2 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

There’s still time to sign up to join the Global Roadshow Prep Course, a one-day virtual training, which includes registration to RESI Partnering Week, September 13-17, with premier partnering access for only $1,950! The course is a hands-on, comprehensive experience designed to set up early-stage life science executives for success as they conduct their global fundraise, with availability on September 3 and September 10.

 Life Science Nation CEO Dennis Ford leads founders through tried-and-true modules targeting branding, messaging, marketing collateral, pitch materials, fundraising principles and strategies, tools for sourcing and developing partnerships, CRMs, outreach, pitching, and follow-up. Learning objectives include, but are not limited to:

  • Branding and messaging communicating your company’s unique story and market value
  • Understanding and creating collateral for use in a pitch setting, including tagline, elevator pitch, executive summary, and slide deck
  • Discovering the values of different types of investors and identifying the best fit -based leads
  • Communicating effectively in order to secure a meeting and following up to develop an ongoing relationship
  • Engaging in successful partnering strategies to obtain funding and strategic partnership

view the agenda

If you’re starting your early-stage fundraising with a RESI conference, set yourself up for success with this companion course and save!

register-now-green

Hear from Past Clients: The Reglagene Story and How They Learned to Tell It

490

Hot Investor Mandate: Established VC with Multiple Offices in USA and Asia Invests Up to $50M in Life Science Companies, Invests in All Stages from Very Early to Growth Stage

2 Sep

A firm with offices in USA and Asia is currently making investments into promising private healthcare companies as well as promising public healthcare companies. The firm invests exclusively in the healthcare sector; the firm invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative product in recent years there; in the USA and other regions, The firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $20-50m, though larger investments are of interest as well; the firm makes investments of typically $5-20 million The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area we are interested and exploring. One of their funds focuses on early-stage opportunities in biotech; though from the main fund, the firm makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based VC Invests in New Life Science and Healthcare Technologies Globally

2 Sep

A Venture Capital firm based in Western Europe invests exclusively in the life science space and is currently investing out of their first fund. The firm looks to invest in early-stage life science companies crossing all sectors and is opportunistic in terms of subsector and indication. The firm focuses on Pre-Seed, Seed, Series A and Series B investments and investments are in the form of equity. The firm makes investments ranging from $50K to $3M per round. The firm will consider opportunities globally.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, digital health, medical device and femtech sectors. The firm is open to pre-clinical companies and all three stages of medical devices. The firm has a broad investment interest and is opportunistic in terms of sub-sectors and indications.

The firm looks for all types of management teams, however a proven track record is a plus. The firm is open to both leading and co-investing. If the firm leads, they seek board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA VC Firm Invests in Seed to Series A Companies with a Focus on Midwest USA-Based Companies, Mostly Interested in Healthcare IT and Digital Health

2 Sep

A Venture Capital Company based in the USA manages three healthcare and life sciences funds for a combined total of $60 million in assets under management. The firm looks to make equity investments of approximately $500k – $1 million into companies with additional capital reserved for follow on rounds. The firm looks to act as a bridge with its investments between the Seed and Series A round. The firm is also open to syndication with other investors for larger deals. The firm focuses its investments in the Midwest but is open to companies located throughout the US and makes approximately 6-8 investments per year.

The firm has recently launched a new healthcare fund in collaboration with another VC firm, and resulting the firm’s focus has shifted more towards Healthcare IT and Digital Health, with a specific focus on how healthcare delivery has changed during the COVID 19 pandemic. Examples of the subsectors of interest are: remote care, Healthcare IT for hospital efficiency, and response infrastructure systems. The firm is opportunistic in terms of indication.

The firm looks for management teams with domain experience, and is comfortable with working with incomplete or scientific founding teams. The firm prefers to take a board seat into companies following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Newly Founded VC Firm Looks For Therapeutics Companies in Europe, With Interests in Oncology Immunology, Rare Disease, and More

2 Sep

A venture capital firm founded in 2021 is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. The firm invests in European companies.

The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →